Research programme: EphB4 receptor/ligand modulators - VasGene

Drug Profile

Research programme: EphB4 receptor/ligand modulators - VasGene

Alternative Names: anti-EphB4 monoclonal antibody - VasGene; EphB4 neutralising Ab - VasGene; EphB4 neutralising antibody - VasGene; EphB4 neutralizing Ab - VasGene; EphB4 receptor tyrosine kinase inhibitor - VasGene; EphB4 RTK inhibitor - VasGene; EphB4 soluble receptor - VasGene; EphB4-131; Ephrin B2 agonist - VasGene; Vas 02; Vas 101; Vas 102; Vas 103; Vas 104; Vas 105; VasG3 MAb; VasG4 MAb; VasG5 MAb

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VasGene Therapeutics
  • Class Antineoplastics; Antisense oligonucleotides; Eye disorder therapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action EphB4 inhibitors; Ephrin-B2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Cancer; Eye-Disorders
  • Discontinued Vascular disorders

Most Recent Events

  • 15 Mar 2018 Preclinical development is ongoing for Cancer, Age-related macular degeneration and Eye disorders in USA (Vasgene Therapeutics pipeline, March 2018)
  • 28 Jan 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Parenteral)
  • 28 Jan 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top